

Doxepin

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2018. Committee Opinion No. 753: Assessment and Treatment of Pregnant Women with Suspected or Confirmed Influenza. *Obstet Gyn* 132(4):e169-e173.
- Aoki FY, et al. 2013. The use of antiviral drugs for influenza: A foundation document for practitioners. *Can J Infect Dis Med Microbiol.* 24(Suppl C) :1-15.
- Beau A-B, et al. 2014. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. *BJOG.* 121(7):895-900. 1-25.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Doxepin

Selected References:

- Ahn KH, et al. 2015. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case-series. *J Clin Toxicol* 5:2
- AlSaad D, et al. 2018. Finasteride use during pregnancy and early neonatal outcome: a case report. *Int J Clin Pharm* 40(4): 803-805.
- Amory JK, et al. 2007. The effect of 5- alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. *J Clin Endocrinol Metab* 92:1659-1665.
- Anderson CA, Clark RL. 1990. External genitalia of the rat: normal development and the histogenesis of 5 alpha-reductase inhibitor-induced abnormalities. *Teratology*;42:483-496.
- Bowman CJ, et al. 2003. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. *Toxicol Sci*; 74:393-406.

- Carlin JR, et al. 1992. Disposition and pharmacokinetics of (14C) finasteride after oral administration in humans. *Drug Metab Dispos Biol Fate Chem*; 20:148-55.
- Cather JC, et al. 1999. Finasteride - An update and review. *Cutis* 64:167-172.
- Ciotta L, et al. 1995. Clinical and endocrine effects of finasteride, a 5(alpha)-reductase inhibitor, in women with idiopathic hirsutism. *Fertil Steril* 64:299-306.
- Clark RL, Anderson CA, Prahalada S et al: Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5(alpha)-reductase inhibitor. *Toxicol Appl Pharmacol* 119:34-40.
- Clark RL, et al. 1990. External genital abnormalities in male rats exposed in utero to finasteride, a 5-alpha reductase inhibitor. *Teratology*; 42:91-100.
- Falsetti L, et al. 1997. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. *Gynecol Endocrinol* 11:251-157.
- Husmann DA, McPhaul MJ. 1991. Time-specific androgen blockade with flutamide inhibits testicular descent in the rat. *Endocrinology*; 129:1409-1416.
- Gupta AK & Talukder M. 2022. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?. *Journal of cosmetic dermatology*, 21(5), 1841-1848.
- Khera M, et al. 2020. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. *Transl Androl Urol* 9(3): 1201-1209.
- Kohler C, et al. 2007. Effect of finasteride 5mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. *Gynecol Endocrinol*; 23:142-145.
- Kurzrock EA, et al. 2000. Urethral development in the fetal rabbit and induction of hypospadias: a model for human development. *J Urol* 164(5):1786-1792.
- Laborde, E. and R. E. Brannigan. 2010. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. *J Androl*; 31(2): e1-2.
- Lumachi F, Rondinone R. 2003. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. *Fertil Steril* 79:942-946.
- Martinez AG, et al. 2011. Effects of in utero exposure to D-004, a lipid extract from *Roystonea regia* fruits, in the male rat: a comparison with finasteride. *J Med Food*. Dec;14(12):1663-9.
- Overstreet JW, et al. 1999. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. *J Urol* 162:1295-1300.
- Paris JJ, et al. 2011. Inhibition of 5 alpha reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progesterone milieu of juvenile rat offspring. *J Neuroendocrinol*; 23(11): 1079-90.
- Prahalada S, et al. 1997. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the Rhesus monkey (*Macaca mulatta*). *Teratology*; 55:119-31.
- Propecia prescribing information. 2020. Accessible from <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e07adb4-7807-47d3-b9a9-2332a3047410#S12.3>
- Ricci G, et al. 2012. Finasteride and fertility: case report and review of the literature. *J Drugs Dermatol*; 11(12):1511-3.
- Rittmaster, RS, 1994. Drug Therapy: Finasteride. *New Engl J Med* 330:120-125.
- Salvarci A, Istanbuluoglu O. 2013. Secondary infertility due to use of low-dose finasteride. *Int Urol Nephrol*; 45(1):83-
- Samplaski MK, et al. 2013. Finasteride use in the male infertility population: effects on semen and hormone parameters. *Fertility and Sterility*; 100:1528-1529.
- Spencer JR, et al. 1991. Effects of flutamide and finasteride on rat testicular descent. *Endocrinology*; 129:741-748.
- Teichert M, et al. 2017. Contraindicated use of 5-alpha-reductase inhibitors in women. *Br J Clin Pharmacol*. 83(2): 429-431
- Wise LD, et al. 1991. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5-alpha-reductase inhibitor. *Reprod Toxicol* 5:353-362

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Doxepin

Selected References:

- Ajiji P, et al. 2021. Investigating the efficacy and safety of metronidazole during pregnancy; A systematic review and meta-analysis. *European Journal of Obstetrics & Gynecology and Reproductive Biology*: **X, 11**, 100128.
- Burtin P, et al. 1995. Safety of metronidazole in pregnancy: a meta-analysis. *Am J Obstet Gynecol* 172(21):525-529.
- Cantu JM & Garcia-Cruz D. 1982. Midline facial defect as a teratogenic effect of metronidazole. *Birth Defects* 18:85-88.
- Caro-Paton T, et al. 1997. Is metronidazole teratogenic? A meta-analysis. *Br J Clin Pharmacol* 44:(2)179-182.
- Cram LF, et al. 2015. Genitourinary infections and their association with preterm labor. *American Family Physician*; 65(2), 241-249.
- Czeizel AE & Rockenbauer M. 1998. A population-based case-control teratologic study of oral metronidazole. *Br J Obstet Gynecol*; 105(3):322-327.
- Finegold SM. 1980. Metronidazole. *Ann Intern Med* 93:585-587.
- Flagyl® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020334s015lbl.pdf.
- Gilbert NM, et al. 2013. Urinary tract infection as a preventable cause of pregnancy complications: Opportunities, challenges, and a global call to action. *Global Advances in Health and Medicine*; 2(5), 59-69.
- Gray MS, et al. 1961. Further observations on metronidazole (Flagyl). *Br J Vener Dis*; 37:278-9.
- Heisterberg L, Branebjerg PE. 1983. Blood and milk concentrations of metronidazole in mothers and infants. *J Perinat Med*; 11:114-20.
- Kazy Z, et al. 2005. Teratogenic potential of vaginal metronidazole treatment during pregnancy. *Eur J Obstet Gynecol Reprod Biol*. 123(2):174-178.
- Koss CA, et al. 2012. Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes. *Antimicrob Agents Chemother* 56(9): 4800-4805.
- Löfmark S, et al. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. *Clinical Infectious Diseases*, 50(S1), S16-S23.
- Muanda FT, et al. 2017. Use of antibiotics during pregnancy and risk of spontaneous abortion. *CMAJ*.

189(17):E625-E633.

- Nwosu OC, Bloom K. The safety of metronidazole in pregnancy. *Health Care Women Int.* 2021;42(4-6):726-738.
- Omranipoor A et al. 2020. Association of antibiotics therapy during pregnancy with spontaneous miscarriage: a systematic review and meta-analysis. *Archives of Gynecology and Obstetrics*302: 5-22.
- Passmore CM, et al. 1988. Metronidazole excretion in human breastmilk and its effect on suckling neonates. *British J Clin Pharmacol* 26(1):45-51.
- Piper JM, et al. 1993. Prenatal use of metronidazole and birth defects: no association. *Obstet Gynecol* 82(3):348-352.
- Rosa FW, et al. 1987. Pregnancy outcomes after first trimester vaginitis drug therapy. *Obstet Gynecol* 69:751-755.
- Sheehy O, et al. 2015. The use of metronidazole during pregnancy: a review of evidence. *Curr Drug Saf.* 10(2):170-9.
- Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*; 64:1-137.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Doxepin

Selected References:

- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. *Breastfeeding Medicine.* 16(8): 591-93.
- Nosedá R, et al. 2024. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. *Clinical pharmacology and therapeutics*, 10.1002/cpt.3269. Advance online publication.
- Praluent® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbledt.pdf, Accessed May 28, 2024
- Vuignier Y, et al. 2021. Exposure to alirocumab during the first trimester of pregnancy: A case report. *Birth*

Defects Research. 113(15): 1156-60.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Doxepin

Selected References:

- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. ***Breastfeeding Medicine.*** 16(8): 591-93.
- Dernoncourt A., et al. 2023. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). *BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy*, 37(1), 73-87.
- Kimball AB. 2020. Pregnancy outcomes in women exposed to guselkumab: Experience from the clinical development program. *J Am Acad Dermatol.* 83(6):AB27.
- McMullan P et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update-Part I: Pregnancy. ***Journal of the American Academy of Dermatology.***
- Tremfya® Prescribing Information. Available online at <http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf>. Accessed on May 28, 2024.
- Wolfe C et al., 2024. A Retrospective Review of Pregnancies in our Psoriasis Biologics Cohort. ***Clinical and Experimental Dermatology.*** 11ae106.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.